TEL-AVIV - RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) ('RedHill' or the 'Company'), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced its decision to discontinue its co-promotion and commercialization agreements for Donnatal and EnteraGam to enable a greater focus on its lead commercial products, Talicia1 and Aemcolo2, and create capacity for additional products.

RedHill provided a notice of termination to Entera Health regarding the license agreement for EnteraGam and the co-promotion agreement with Advanz Pharma Corp. for Donnatal will not be renewed. RedHill has been promoting Donnatal and EnteraGam since mid-2017.

'Prioritizing our commercial efforts allows us to focus on our most valuable products, Talicia and Aemcolo, as well as giving us capacity to bring on other important products, which are currently under discussion' said Dror Ben-Asher, RedHill's Chief Executive Officer. 'Over the past 2.5 years, we've established a full U.S. commercial operation including a seasoned sales force, and built relationships with thousands of gastroenterologists, primary care and other healthcare providers across the country ahead of the planned Talicia launch later this quarter. We would like to thank our partners at Advanz Pharma and Entera Health for the fruitful partnerships.'

RedHill initiated promotion of Aemcolo in the U.S. in December 2019. Talicia was approved by the U.S. FDA in November 2019 and is planned to be launched in the first quarter of 2020.

About RedHill Biopharma Ltd.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company, primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases. RedHill promotes the gastrointestinal drugs Aemcolo and Mytesi in the U.S. and is planning to launch Talicia in the U.S. for the treatment of Helicobacter pylori (H. pylori) infection in adults3. RedHill's key clinical late-stage development programs include: (i) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (ii) RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (iii) RHB-102 (Bekinda), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (iv) ABC294640 (Yeliva), a first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 2a study for cholangiocarcinoma; (v) RHB-106, an encapsulated bowel preparation, and (vi) RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases.

Contact:

Adi Frish

Tel: +972-54-6543-112

Email: adi@redhillbio.com

(C) 2020 Electronic News Publishing, source ENP Newswire